Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.28 USD | +0.31% | -4.37% | -38.69% |
May. 07 | Transcript : Harvard Bioscience, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 Revenue $24.5M | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-38.69% | 142M | D | ||
+10.59% | 227B | B | ||
+15.31% | 198B | B- | ||
+18.40% | 142B | B- | ||
+30.96% | 111B | A- | ||
+1.56% | 64.16B | A- | ||
+18.44% | 54.1B | B+ | ||
+5.12% | 51.41B | B+ | ||
+10.85% | 45.32B | A | ||
+5.35% | 37.32B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HBIO Stock
- Ratings Harvard Bioscience, Inc.